Sutro Biopharma (STRO)
Develops site-specific and dual-payload antibody-drug conjugates for oncology using cell-free protein synthesis.
$20.47
At close−0.35 (−1.68%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions72 holders · as of Mar 31, 2026 | 85.01% | 14.10M shares | |
| Insiders11 holders · as of Jun 2, 2026 | 0.75% | 124.3K shares | |
| Otherremainder | 14.24% | 2.36M shares |
16.58M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (16.58M in the company's Sep 3, 2026 report, 9.68M elsewhere); stakes use the report.
Institutions13F, as of Mar 31, 2026
72 holders · 14.10M shares · 26 new positions · 47 increased · 13 reduced · 17 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BVF Inc/IL | 1.25M | 7.55% | +1.25Mnew | May 15, 2026 |
| Affinity Asset Advisors, LLC | 1.07M | 6.45% | +321.1K | May 14, 2026 |
| Samsara Biocapital, LLC | 1.06M | 6.41% | +858.4K | May 15, 2026 |
| Kynam Capital Management, LP | 872.6K | 5.26% | +393.0K | May 15, 2026 |
| Orbimed Advisors LLC | 801.1K | 4.83% | +801.1Knew | May 15, 2026 |
| Vanguard Capital Management LLC | 720.4K | 4.34% | +720.4Knew | May 15, 2026 |
| Perceptive Advisors LLC | 715.3K | 4.31% | +715.3Knew | May 29, 2026 |
| Ra Capital Management, L.P. | 715.3K | 4.31% | +715.3Knew | May 15, 2026 |
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Affinity Healthcare Fund, LP | 7.77% | 13G | Oct 23, 2025 ↗ | |
| Affinity Asset Advisors, LLC | 6.50% | 1.07M | 13G | May 14, 2026 ↗ |
| BlackRock, Inc. | 6.40% | 1.07M | 13G | Jul 30, 2026 ↗ |
| Point72 Asset Management, L.P. | 5.70% | 946.8K | 13G | May 1, 2026 ↗ |
| Millennium Management LLC | 5.60% | 13G | Jun 30, 2025 ↗ | |
| Perceptive Advisors LLC | 5.40% | 898.0K | 13G | Apr 21, 2026 ↗ |
| Kynam Capital Management, LP | 5.27% | 0 | 13G | May 15, 2026 ↗ |
Insider tradesForm 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Oct 15, 2025 | David Paulingofficer: Chief Admin. Ofcr. & GC | Purchase | 12,504 | $0.7992 | 71,737 |
| Oct 15, 2025 | Connie Matsuidirector | Purchase | 50,000 | $0.7990 | 50,000 |
| Oct 15, 2025 | Jane Chungdirector, officer: Chief Executive Officer | Purchase | 12,500 | $0.8009 | 122,850 |
| Oct 15, 2025 | Gregory K. Chowofficer: CFO | Purchase | 19,750 | $0.8100 | 19,750 |
| Oct 15, 2025 | Hans-Peter Gerberofficer: CHIEF SCIENTIFIC OFFICER | Purchase | 17,000 | $0.8004 | 71,832 |
CongressHouse and Senate disclosures
Not reported.